Thu. 28 Mar 2024, 8:08am ET
Benzinga
Earnings, News
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.73) by 17.81 percent. This is a 7.5 percent decrease over losses of $(0.80) per share from the same period last year.